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MODERN CONCEPTS OF BREAST 
CARCINOMA
By SIR A R TH U R  PO RRITT
K.C.M.G., C.B.E., M.A., M.Ch., F.R.C.S.
Sergeant Surgeon to H .M . the Queen
t w e n t y  y e a r s  a g o ,  it was generally considered that breast cancer was 
readily accessible to radical surgery and that radical surgery had more 
to offer here than perhaps anywhere else in the body. In the intervening 
years, this pseudo-complacency has suffered a series of rude shocks, until 
to-day the pendulum has swung full distance and radical mastectomy 
plays but a minor role in the treatment of carcinoma of the breast. The 
now obvious gaps in our armamentarium have been filled by X-ray 
therapy, with or without local surgery, by the use of the sex endocrines 
and the cortico-steroids and by what may be termed “ physiological” 
operations on various endocrine glands.
In the mid-thirties, the surgeon could accept full responsibility for 
treatment by the use of his technical skill. Nowadays, however, each 
individual patient, and almost each individual cancer, demands such nicety 
of judgment and keenness of assessment, if the correct method or com­
bination of methods is to be used, that the surgeon must enlist the 
co-operation of those of his colleagues who specialise in radiotherapy, in 
histo-pathology and in steroid chemistry.
The complexity of the subject of breast cancer therapy is now all 
too obvious and many of us feel we are groping in a very stimulating 
but very perplexing dark. Hence, there may be some value in a general 
surgeon, who can contribute little new to the problem, attempting a 
summary of the existing situation.
Such is the breadth of knowledge now required and so great is the 
accumulation of new facts and theories concerned that even my thirty 
years of clinical experience seem an indifferent qualification for the 
task. Such experience, however, does indelibly impress upon one’s mind 
and on one’s heart that breasts belong to people ! And these people, 
our patients, are well aware not only of the dual functions of the breast 
for lactation and decoration, but also of the sword of Damocles that hangs 
over them in the sinister shape of carcinoma. I do not intend to enlarge 
upon this aspect save to stress the vital importance to the patient of 
undergoing any form of treatment which may involve disfigurement or 
mutilation. Many patients will state, quite honestly, that they would 
prefer to keep their carcinoma rather than submit to radical mastectomy.
The breast is so readily accessible to the patient, and she is usually 
so well aware, either subjectively or in fact, of pathological changes 
in it, that in no sphere of clinical surgery can that much-maligned phrase 
“ the doctor-patient relationship” be more profitably exercised or the milk 
of human kindness be more sympathetically expended.
May I first consider briefly some points relative to the history, 
incidence, aetiology, clinical picture and prognosis of the disease?
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History
From the detailed description of what he termed “ Bulging tumours of 
the Breast,” it would seem that the great Egyptian surgeon of 3000 B . C . ,  
Imhotep, recognised breast carcinoma as an entity. His findings are 
recorded in the Edwin Smith Sugical Papyrus and probably constitute the 
first written word on this dire disease. Hippocrates was well aware of it 
and enunciated the odd theory that bleeding from the nipple was a sign 
of madness. Celsus, in 100 B.C., advocated the treatment of mammary 
carcinoma by caustics; this method retained its popularity for centuries 
and was, amazingly enough, used in this country as recently as the 1860’s. 
Sir D ’Arcy Power recalled having seen two cases so treated in his youth 
and I believe these two specimens are still to be seen in the museum of 
St Bartholomew’s Hospital. Neither must we forget the name of Galen 
in this connection, for it was he who likened the disease to a crab and 
thus gave it the name which has lasted to this day. From descriptions 
in medieval literature, it would seem that only very advanced and usually 
fungating, cancers came to light and these were treated surgically by 
operations, deservedly labelled “ amputations.”  Many illustrations in 
ancient books can still be found showing a weird variety of slices, shears 
and clamps used for this purpose, and the accompanying rope tied round 
the base of the breast as a form of tourniquet was a well-known feature.
The first form of planned mastectomy was probably carried out by 
Jean Petit in the early seventeen hundreds, but more than a hundred 
years had still to pass before we come to the great pioneers of breast 
surgery, to whom we should surely pay homage, Charles Moore, Mitchell 
Banks, Sampson Handley and Cheatle in this country, and Pancoast, 
Samuel Gross and Halsted in America. All these men worked on the 
hypothesis that to eradicate breast carcinoma, as well as the tumour itself, 
all areas of lymphatic drainage that were surgically accessible should be 
cleared. Charles Moore, of the Middlesex Hospital, first practised the 
removal of the pectoral muscles and their accompanying lymphatic chains 
in 1867. Some ten years later, Mitchell Banks of Liverpool described his 
axillary clearance and, in 1889, Halsted of Baltimore introduced a radical 
mastectomy which is still the prototype of all radical mastectomies done 
to-day. This is surely a wonderful tribute both to the man and his method. 
Re-orientation of our ideas on this subject has served only to limit the 
scope of the operation and not to decry its technique or rationale.
Incidence
I have already used the words “ dire disease” and this carcinoma of 
the breast most certainly is. Statistical evidence seems to show quite 
definitely that, even allowing for a slow increase in the average age 
of the population, its incidence has specifically increased in the last thirty 
years. It accounts for approximately one-third of all malignant neoplasms 
in women ; one woman in every twenty of adult age acquires i t ; it kills 
over 7000 women every year in this country. But, unlike certain other 
growths, it flourishes in almost every clime and every quarter of the globe, 
and now has the sinister reputation of having outstripped its partner in 
crime, carcinoma of the uterus, as the most lethal carcinoma in women.
Its peak incidence is certainly in the menopausal years, particularly 
when this period is either delayed or protracted. The rather futile contro­
versy as to which breast is the more frequently attacked still goes on, 
but the stress laid of recent years on endocrine influence gives more point
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to the equally debated question as to whether the breast that has lactated 
is more likely to develop cancer than the virginal breast or vice versa.
Aetiology
In respect of aetiology, carcinoma of the breast differs little from its 
fellows elsewhere in the body. Theories are rampant, facts are few. 
Bittner’s discovery of his “ milk factor” in 1936 stimulated a genetic 
approach. The action of this virus-like agent, transmitting dominantly 
through the female mammary tumors to suckling mice and, at the same 
time, producing anti-carcinogenic antibodies, has unfortunately never 
been established in the human. But few will deny that a familial trend 
exists not only towards carcinoma in general but more specifically to 
carcinoma of the breast itself. Jacobson of Denmark, some ten years 
ago, however, favoured the theory of a general cancer gene, transmitted 
according to Mandelian principles and estimated by him to be present 
in approximately 10% of the population. Only much time, together 
with detailed statistical work, could prove or disprove this conception. 
Whether such a genetic or familial trend does or does not exist, there 
is no doubt that the factor of chronic irritation is a potent one in breast 
carcinoma. It has been truly said that carcinoma of the breast thrives 
in an environment of oestrogens, a fact which almost certainly accounts 
for its marked predominance in women and probably also for the fulminat­
ing characteristics of pregnancy carcinoma, when the placenta adds its 
considerable quota of oestrogens to those already present. Throughout 
a woman’s functional life, the breast responds in varying degree to a 
repeated cyclical stimulation from oestrogens which leads in a proportion 
of patients, to the cystic degeneration of fibro-adenosis. Again, the 
stagnant secretions of the breast, particularly after lactation, have been 
indicted as potential irritants. Yet one more thought is perhaps worthy 
of consideration in this respect: two out of every three carcinomata of 
the breast occur in the outer quadrants. The difference in tissue mass 
as represented by the axillary tail is so small that the probability of 
multiple minor traumata should perhaps be entertained. In other tissue, 
the carcinogenic significance of repeated trauma is well enough established.
Clinical Picture
No detailed description of the clinical picture is called for in this lecture 
but perhaps one or two salient points merit attention. The contro­
versial question of “ staging” still awaits solution. The fallacies 
of clinical staging become more obvious every day, even admitting a 
certain degree of international unanimity in definition of the various 
stages. Surgical or operative staging, pathological staging and histo­
logical staging, all show how erroneous the first clinical assessment can 
be. Axillary glands, the crucial factor in correlating clinical findings to 
therapy, are clinically missed in as many as 50% of cases and, when 
found, by no means always harbour metastases. Add to this the findings 
of Sampson Handley and Scarff, that one-third of all cases and 50% 
of inner quadrant cases produce clinically undiscoverable internal mammary 
and mediastinal glands and the value of clinical staging, except for pre­
liminary descriptive purposes, seems to get smaller and smaller.
The importance of the doubtful lump, however, becomes greater as 
the education of the lay public extends. If every doubtful lump in the
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breast were discovered, reported and dealt with whilst still covered by 
that label, the figures for carcinoma of the breast would undergo a magical 
transformation. I still like to use, both to patient and student, those 
three excellent aphorisms of Riddell—
“ The period of observation is the period of lost opportunity” ;
“ No lady keeps a lump in her breast” ; and
“ Beware the ample bosom.”
The clinical diagnosis of carcinoma of the breast is not as easy as 
the text-books used to lead us to believe. The doubtful lump is far 
commoner than the classical carcinoma and it is the former that will 
produce therapeutic dividends. After all. it is the survival of the patient 
that counts.
In this connection, one must always bear in mind the fact, which is 
now well established, that the average span of life in untreated carcinoma 
of the breast is three years. Hence, figures of three years’ survival after 
treatment are relatively worthless. It seems obvious that the disease runs 
a natural course, that there are certain factors which expedite that course 
and others which delay it, some almost indefinitely. In treatment, we 
break into the natural course for better or for worse, and it needs 
the keenest judgment to decide if and how, and where, to make that break.
Prognosis
Carcinoma of the breast, being so readily accessible clinically, affords 
numerous examples of what Gordon-Taylor has described as “ cancer 
immunity.” The atrophic scirrhus of the eighty-year-old patient which she 
has knowingly kept for twenty or thirty years is a classical example. In ­
prognosis, the rate of growth is infinitely more important than the duration 
of symptoms. The lethal encephaloid cancer often kills the patient without 
producing a single metastasis. Again, quite frequently, long intervals of 
many years may transpire before secondary growths, which must pre­
sumably have been in situ before the primary was removed, effloresce into 
further and very fatal activity. This represents a breakdown in immunity 
and such a failure of the natural mechanism is usually a concomitant 
of other quiet unrelated illnesses. These happenings, and even the well- 
authenticated actual disappearance of some tumours, all offer very 
intriguing problems which are probably associated more with the aetiology 
of cancer as a whole rather than of the breast in particular.
Age is undoubtedly a factor in prognosis and, despite the widely held 
belief that the younger the patient the worse the outlook, Macdonald has 
recently produced figures to show that the immediate post-menopausal 
years (50-60 age group) are probably the most dangerous. It has only 
recently become appreciated that, at this stage, oestrogen production is 
not as deficient as was formerly thought.
Before delving deeper into a consideration of methods of treatment 
to-day, I feel I should list the series of jolts which personally destroyed 
my complacency in the belief in which I had been brought up, that for 
all cases of breast carcinoma, which were not. obviously hopeless and 
moribund, the answer was radical mastectomy. They were :
(i) Thoughts about the hormone dependency of carcinoma of the 
prostate and the fact that oestrogen therapy in man had pro­
duced carcinoma of the breast.
(ii) The summary from St Bartholomew’s Hospital, produced by
Murley and his colleagues, showing that, over a period of ten
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years, the results of treatment (irrespective of surgeon and 
and irrespective of method) showed a miserable 1 % difference 
in survival rates.
(iii) The work of Sampson-Handley (1952) on the frequency of 
lymphatic spread of growth to the internal mammary and 
mediastinal glands.
(iv) The great advances in endocrine chemistry and their application 
to the problem of breast carcinoma, by surgery of the various 
endocrine glands and by sex hormone and steroid administration.
These developments seemed logically to push the pendulum of therapy 
further and further away from the radical surgery of the preceding sixty 
years. To-day, it would almost appear we have come to the point where, 
not only has the field of local surgery, that is surgery of the breast itself, 
dwindled to minor proportions, but where we must honestly face up to  
the question as to whether surgical therapy is indicated at all.
I feel one has only to ask this question to get at least a qualified 
affirmative but to decide into which class any particular growth, and 
any particular patient, falls is a matter of infinite difficulty. Even when 
one decides that treatment is indicated, which will obviously still be the 
case in the majority until our knowledge expands yet further, we now 
possess a great series of therapeutic weapons, besides mere local cutting, 
and their use, alone or in combination, requires almost the judgment 
of a Solomon.
Treatment
t h i s  may be very simply summarised as follows :
(Ultra-radical Radical w i t h  o r  Deep
Palliative without therapy
(AlonePre-operative
Post-operative
{Oestrogens Androgens Cortisone
IV ENDOCRINE ( Oophorectomy
SU RGERY Adrenalectomy
I Hypophysectomy
V SYMPTOMATIC
It is obviously not easy to get all these various methods into per­
spective and it may be profitable first to discuss each as an entity and 
then to try and link them in combinations likely to give the best therapeutic 
results to each individual growth and patient. It will be immediately 
apparent, however, that surgery on the breast alone has but a limited 
scope. And that, to my mind, poses the first major question to be 
answered— “ What now is the field of radical surgery?”
r a d i c a l  s u r g e r y . —Unless, with all the knowledge we now possess 
and all the data we can accumulate in any particular case, we can honestly 
expect to extirpate the disease, lock, stock and barrel, then there is no 
excuse for the major mutilation involved. This is not the place to enlarge 
on the psychological effects of removal of the breast, but it is most certainly 
a matter that must be constantly in the forefront of our minds. Very few 
women can completely readjust mentally to the loss of a breast, valiant 
though their efforts may be. The absence of such an obvious physical
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feature is a constant reminder of the sword of Damocles that has hung, 
and for all they know or are told, still hangs over them. The hiatus 
engenders almost as much, and sometimes more, mental trauma than 
did the original lump in the breast. This all-important fact and the 
accumulation of statistics of survival periods over now a long period of 
years, have given a new orientation to the value of radical mastectomy. 
There is no doubt, however, that the Halsted operation, which as a 
technical exercise has most certainly worthily stood the test of time 
and has now a world mortality of under 1 %, can, in well-chosen cases, 
effect something as near a cure of breast cancer as anything we know. 
The choice— to mutilate or not to mutilate— depends essentially on the 
clinical presence of glands, apparent or presumed. There are those who 
believe that the lymphatic nodes, on the analogy of infection, are effective 
blocks in the path of spread and that to remove them by surgical dissection 
is deliberately to break down natural barriers. Professor McW hirter and 
his School here in Edinburgh, are the great protagonists of this belief, 
and it would certainly seem that figures amply bear out their hypothesis.
In other words, nodes, unless minimal, are a contra-indication to radical 
surgery for they indicate a spread of the disease beyond the scope of 
surgical extirpation.
Therefore, the Halsted type of mastectomy should be limited to the 
case which is genuinely clinical Stage I-—a lump in the breast with no 
clinical axillary glands. To this, one must add Sampson Handley’s 
findings in respect of internal mammary gland involvement, which would  
logically limit the cases suitable for radical mastectomy to Stage I growths 
in the two outer quadrants only. In such cases, one may reasonably 
expect a five-year-survival rate of 80% and a ten-year-survival rate of 
60-65% and these figures undoubtedly justify the mutilation involved. In 
this connection, it may be mentioned that adjuvant radiotherapy seems 
to effect no improvement in these figures and, therefore,- it can fairly 
be said that, in this very limited field, surgery, and surgery alone, still 
offers optimum results.
It must be mentioned, however, that there is a small, but active school 
which sees in the new developments a challenge to surgey and which has 
extended the scope of the radical operation to include the removal of even 
wider fields of possible spread. Urban, in 1954, advocated and practised 
such an ablation which consisted of the lateral third of the sternum, the 
costal cartilages, the internal mammary vessels and their concurrent 
lymphatic chains and the supraclavicular glands and, of course, a full 
axillary clearance in addition. To a modified degree, Sampson Handley 
has extended the scope of the original radical mastectomy and it is not 
without historical interest to remember that Halsted himself, in his earlier 
days, included the homo-lateral supraclavicular glands in the scope of 
his dissections. Such heroic extirpations as Urban’s must, of necessity, 
add to the morbidity and mortality of the operation and it remains to 
be seen whether ends will justify means.
p a l l i a t i v e  s u r g e r y . — Going to the other extreme, once one has 
admitted the limitation of a radical operation and has frankly faced up 
to the fact that, in a particular case, the main therapeutic attack is not 
to be operative, there still remains a large and useful field of minor or 
palliative breast surgery. Professor M cW hirter’s contention that a 
removal of breast disc alone, together with X-ray therapy to control local 
recurrences, is better than radical mastectomy, is amply borne out by 
his figures which, to date, show an over-all 5% advantage for the simpler
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methods and this figure has deservedly received world-wide attention. 
His results have been even better in Stage .II growths than in Stage I 
growths and constitute a very definite advance in surgical thought on this 
most difficult problem.
If there is anything original I can personally offer in this question, 
it is work along similar lines which I began with the help of my radio- 
therapeutic colleague, Dr M. Hulbert at St M ary’s Hospital some seven 
years ago. W e have been even more conservative than McWhirter and 
have worked on the basis that, if surgery is not meant to be the main 
line of defence, it should not mutilate; I have removed simply the lump 
itself and a wedge of surrounding breast tissue and left the disc in situ. 
This has been combined in most cases with a very modified exposure of 
the axilla to prove or confute clinical findings in respect of axillary nodes 
and to obtain a suitable gland for biopsy and prognosis purposes. Each 
case has received adequate radiotherapy to those areas suggested as 
necessary by the clinical and surgical findings. Results to date are not 
sufficiently numerous to be statistically significant but the trend is quite 
obvious and follows exactly that of Professor McWhirter, showing a 
small but definite advantage in favour of the minor procedure in com­
parison to a parallel series of radical mastectomies. Moreover, there is 
the added advantage of a series of very grateful patients who have not lost 
their breasts.
I need not here do more than mention the obvious value of palliative 
surgery in dealing with the breast carcinoma that is about to fungate or has, 
in fact, fungated through the skin, though this again is a field where 
radiotherapy can be of the greatest use.
r a d i o t h e r a p y . - — If we general surgeons are completely honest with 
ourselves, I think we regard X-ray therapy with an odd mixture of awe, 
doubt and respect! W e have all seen the great relief it can give 
to frankly inoperable cases, both at the site of the growth and elsewhere; 
we have all frankly admired it for turning an inoperable case into an 
operable one, and we have all used it in the fond belief that it would be 
wrong not to twang every string in the therapeutic bow, however little 
we may know of its friability or its strength.
But the days when radiotherapy was looked on as the hand-maiden 
of mastectomy are past. It is an accurate and scientific therapeutic method 
in its own right and can be used as the sole method of treatment in 
certain selected cases of breast carcinoma. Its position in the therapeutic 
armamentarium can be likened to that of a Dominion in the Commonwealth; 
it has a domestic sphere of influence of its own and unites with the other 
“ Dominions” of endocrine therapy and endocrine surgery to assist the 
“ Mother Country” of General Surgery in an all-out attack in time of 
danger.
The potency and accuracy of radiotherapy have greatly increased over 
recent years with the arrival on the scene of the megavolt machine, the 
linear accelerator and the cobalt units. There would now seem no vestige 
of doubt that ray therapy can inhibit and even completely destroy neoplastic 
activity, and achieve this without mutilation and without mortality. Where 
to draw the dividing line between inhibition and destruction, with reference 
to the effect on normal tissues, is still a matter of debate. Many examples 
have been given of active cancer cells found locked up in the firm fibrosis 
of a gland treated by deep X-ray therapy. The dosage lethal to neoplastic 
cells lies very near, if not beyond, the tolerance dose of normal skin. 
Breast tissue, on the other hand, is of relatively low susceptibility. If
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recurrencies do occur after radiotherapy, they are notoriously resistant 
to further treatment. On the debit side of the balance, too, must be 
placed the quite definite, though admittedly temporary, physical discomfort, 
mental lethargy and depression which commonly accompany this form 
of therapy.
In using irradiation, just as much sound judgment and keen clinical 
and pathological assessment of a particular case are required as when 
surgical measures are contemplated. There are undoubtedly some cases 
which are resistant to radiotherapy from the start and, if it is given to 
such cases, spread seems to be accelerated and the actual areas treated 
tend to harbour metastases.
If used in conjunction with surgery, as is nowadays almost a routine, 
except perhaps for the genuine Stage I growth in the outer quadrants, 
its sphere can at first be limited according to glandular involvement, either 
surgical or pathological. It is wise, after operation, to leave sufficient 
interval to ensure good wound healing before starting treatment. 
Indifferent wound healing is one of the chief arguments, though not 
really a very cogent one, against pre-operative irradiation, as such treat­
ment has a negligible effect on the technique of subsequent surgery.
Irradiation therapy produces its optimal effects in clinical Stages II 
and III. To give some idea of its value, the following average figures 
of a number of series may be quoted. In Stage II, the 10-year survival 
rate with surgery alone amounts to 25% on ly; if deep X-ray therapy has 
also been used, this figure is increased to 32%. In Stage II I , surgery alone 
can claim only a 7% ten-year survival rate; surgery and irradiation, 
9%, and radiotherapy alone 13% . In the later stages of the disease, 
when widespread dissemination has occurred, radiotherapy finds its 
greatest value in the relief of pain due to osseous deposits.
Before leaving the subject of irradiation, mention should perhaps be 
made of Pannett’s recent intriguing suggestion that the benefit derived 
from ray therapy comes not from the direct effect on the cancer cell but 
from chemical changes produced in the surrounding normal cells, which 
are stimulated to produce chemical substances lethal to the neoplastic cell 
contained in their midst. This work derives from the original observations 
of Keynes in the early thirties, when he reported the disappearance of 
breast cancers surrounded by a ring of radium needles, a method similar 
to that used in the treatment of cancer of the tongue.
In introducing the next group of therapeutic measures available in 
treating breast carcinoma, it must be stressed that they have a value 
only in the so-called “ hormone-dependent” growths which regrettably 
make up only some 45% at the most of all breast cancers. For the 
remainder, surgery and irradiation offer all that is available. But, for 
this 45%, if they can be identified, the field of therapy has, of recent 
years, expanded in a most dramatic manner. Heretofore, this identification 
has been by trial and error and the whole subject has been on a purely 
empirical basis. Only after protracted courses of hormone therapy or 
having undergone major operations on the endocrine glands, could the 
unfortunate patient be told that her growth was not hormone dependent. 
Histological examination of the tumor often gives a good lead in making 
a decision on dependency for the greater the cellular differentiation of the 
growth, the greater the likelihood of its being dependent. Again, the 
age of the patient was assumed to be a reasonable pointer. The younger 
patients produce a much higher proportion of dependent tumours because 
their oestrogen output is relatively so much greater. Even now, doubt
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is being cast on the oestrogens as the only hormone involved, and the 
work of Skowen and Hadfield recently stresses the importance of 
pituitary prolactin as a potent force. From their research, the possibility 
of a breast cancer stimulated entirely by a pituitary hormone certainly 
cannot be ruled out and proof is more than presumptive that, even if 
this is not so, the pituitary and ovarian hormones are synergistic in their 
influence on mammary carcinoma.
To-day, however, it is possible, by a number of bio-assays, chemical 
estimations and clinical tests, to prove that a particular growth is hormone- 
dependent. We have passed from the empirical state of qualitative 
endocrinology to the quantitative. Certain laboratory estimations and 
assays have now been developed which make possible two clinical tests 
that go a long way to prove the hormone dependency or otherwise of any 
given tumour.
In the blood, a raised serum calcium and a raised alkaline phosphatase 
are both indications of the likelihood of osseous metastases, whilst a 
raised acid phosphatase points more to visceral secondary deposits. Calcium 
excretion in the urine is a good index of bone destruction and can be 
estimated quantitatively. As a round guide, it can be said that every 
100 mg. of urinary calcium represent 1 g. loss of skeletal bone. 
The endocrine assays are a more recent development. F .S . H. estima­
tions show indirectly the patient’s oestrogen activity, and it is well to 
remember that the more oestrogens the more growth. Since oestrogens 
inhibit the pituitary, the more F .S .H . the less oestrogen.
By the bio-assay method of Allen and Doisy, however, it is now 
possible to estimate oestrogen levels directly and to divide them into their 
“ To” and “ Tzn” fractions. After a normal menopause, F .S .H . values 
are high, but in cases of cortical stromal hyperplasia, an opposite trend 
is noticed and oestrogen values, especially of the “ Tzn” fraction, rise 
sometimes to phenomenal heights, especially in cases of breast carcinoma. 
Hadfield’s urinary assays of mammotrophic hormones in the urine have 
provided a most useful guide to the potential value of hypophysectomy.
The two clinical tests which can be applied to any patient with breast 
carcinoma and particularly those in the advanced stage, where hormone 
therapy or endocrine surgery is being contemplated, are as follows :
1. The Stilboestrol Stimulation Test is self-explanatory. The exhibi­
tion of stilboestrol produces both a raised serum calcium and a raised 
urine calcium excretion, together with an obvious worsening of symptoms, 
especially pain, in any patient whose growth is hormone-dependent. The 
trial dose of stilboestrol is usually 10 mg. daily for three days, and the 
effects of this in a susceptible case may last for as long as a month. 
The test should not be used in patients with poor renal function. It is 
hardly necessary to say that the raised calcium figures will apply only to 
cases with osseous metastases.
2. Cortisone Inhibition T e s t : Here, the effect is just the opposite 
and, together with amelioration of clinical symptoms, there is a marked 
fall in urinary calcium excretion. The usual dose of cortisone given is 
200 mg. daily for three days, followed by 10 0  mg. daily for as long as 
required.
Without previous oophorectomy, the test, of course, loses its value.
One may now, perhaps, say a few words about the specific uses of 
the several hormones used in therapy and the operations performed to 
regulate their activity.
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Hormone Therapy
Oestrogens : Stilboestrol (usually prescribed in the form of dinoestrol) 
finds its chief use in the treatment of the elderly patient. In such a case 
where the natural supply of oestrogens has dried up, stilboestrol, probably 
by acting as a pituitary depressant, actually inhibits the growth which, 
in an earlier age group, it would have stimulated. It is this latter fact 
which underlines the danger of the rather wholesale prescribing of 
stilboestrol for the pains of fibro-adenosis that is so prevalent to-day.
In general, therefore, stilboestrol should not be used before the meno­
pause, nor is it wise to use it in cases where there is a family history 
of carcinoma, or where the disease presents with bleeding from the nipple. 
Beneficial effects arc best shown on visceral metastases, but side-effects 
are not uncommon, particularly subcutaneous oedema due to salt and water 
retention, pain in the breast, uterine bleeding and nausea. In those 
cases which react favourably, about 40% of visceral metastases and 
30% of osseous, the remission can be expected to last up to two years 
or more.
Androgens are usually given in the form of testosterone propionate, 
and are chiefly used in the pre-menopausal patient. Such temporary 
remission of symptoms as they produce, especially of pain in the case 
of osseous secondaries and in the late exacerbations following adrena­
lectomy, occur in not much more than 20% of cases and rarely does the 
improvement last more than a year. Side effects of masculinisation are 
common. It would probably be fair to say that the androgens never 
produce such a good effect as oophorectomy, but they can be used after 
this operation with advantage, to enhance the effect.
Cortisone : Steroid medication inhibits both adrenal and pituitary 
function and it is most important to bear this fact in mind when assessing 
the results of adrenalectomy. After this operation the administration of 
cortisone becomes essential and it seems not improbable that the apparently 
beneficial effects of adrenalectomy are, in fact, due directly to the replace­
ment doses of cortisone and not to the adrenal ablation. Adrenalectomy 
is known to produce a marked increase in both ACTH  and mammotrophic 
hormones and, therefore, it is possible, in tumours which are pituitary- 
dependent, that adrenalectomy may, in fact, do harm that will auto­
matically be corrected by the subsequent giving of cortisone. It is 
believed, by some workers, that cortisone has a direct action in that 
it competes with oestrogen for protein molecules in the circulating blood 
and, as the oestrogens have the greater affinity, very large doses of 
cortisone are required to displace them. Hence the possibility of ultimate 
“ escape” from cortisone effect when the dosage becomes so heavy as 
to produce such well-marked side-effects as “ moon-face” and peptic 
ulceration. Such an “ escape” usually occurs within a two-year period 
from the start of cortisone therapy. To-day, cortisone is most frequently 
exhibited in the form of prednisone, which has less tendency to lead to 
distressing side-effects.'
Endocrine Surgery
In considering endocrine surgery, what has been so forcibly termed 
elsewhere “ a series of planned rearguard actions” implies that the battle 
has been already lost and one is only “ staving off” the inevitable. But 
it is also fair to say that the three operations of oophorectomy, adrena­
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lectomy and hypophysectomy have given months, and even years, of 
life with great improvement of symptoms, to cases which must otherwise 
have perished out of hand. At the risk of being repetitive, it must be 
stressed again that good can be done only in those cases in which the 
growth is hormone-dependent and that these number less than 50% of 
the total.
o o p h o r e c t o m y .  —This was practised empirically for cases of breast 
carcinoma as long ago as 1896. It probably fell into disrepute because, 
at that time, it was not appreciated that its possible sphere of usefulness 
was so limited and, if all cases were treated by ovarian ablation, the 
results would certainly not recommend the operation.
Its possible value would seem to be greatest obviously where urinary 
oestrogen values are highest, that is in pre-menopausal patients particu­
larly and, to a lesser extent, in menopausal cases which form a 
relatively large group, and in those post-menopausal women who have 
cortical stromal hyperplasia of the ovaries. In passing, it should be noted 
that breast carcinoma has been reported to occur in 2% of previously 
castrated women.
Regarding the method of producing castration, there seems to-day a 
consensus of opinion that surgical removal gives a definitely more com­
plete and effective result than irradiation.
a d r e n a l e c t o m y  must be combined with, or follow, oophorectomy if 
j t  is to achieve beneficial results in the treatment of advanced hormone-, 
dependent breast cancer. In such cases, which can now be identified 
by a good response to the cortisone inhibition test, the remaining oestrogen 
factory producing mainly the “ Tzn” fraction, is removed. The operation 
has small value where the metastases are heptic, cerebral or pulmonary, but 
osseous deposits particularly and, to a lesser extent, skin secondaries, 
are favourably affected. The leading protagonist of the operation in this 
country, Stanford Cade, claims approximately 100% satisfactory remissions 
in castrated women, one-third of these being benefited for periods of two 
years or more. The best results appear to occur in those cases where 
the original breast growth was not a scirrhus carcinoma. However, the 
operation carries an appreciable mortality (12-15%) a n d  its  difficulty lies 
chiefly in the complete eradication of adrenal tissue. It is estimated 
that about one-third of the patients have accessary adrenal tissue outside 
the actual gland itself. There seems considerable basis for the belief that 
oophorectomy, combined with cortisone therapy, achieves as much as 
the technically difficult operation of adrenalectomy.
h y p o p h y s e c t o m y  is, at the moment, the last ditch in the hormonal- 
surgical attack on advanced mammary carcinoma. Heretofore, it has 
been difficult to select suitable cases, except on a purely empirical basis, 
but Hadfield’s recent work in estimating urinary prolactin may give a 
very useful pointer.
At least half the cases submitted to this operation obtain a very 
definite symptomatic improvement, and this percentage may well be 
increased when selection is more accurate. The operation, of course, 
demands the very specialised technique of a skilled neuro-surgeon. It has 
the advantage that it does not produce the pronounced upsurge of 
mammatrophic activity that adrenalectomy does. In fact, the post­
operative management of a case of hypophysectomy is much easier if
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the adrenals are still intact. Adrenalectomy preceding hypophysectomy 
tends to produce a very marked instability of fluid and electrolytic balance.
The side-effects of hypophysectomy must be borne in mind. Approxi­
mately half the cases will get subsequent diabetes insipidus and all will 
show greatly decreased thyroid function. Such a state of affairs calls for 
permanent post-operative treatment in either or both of these directions.
Conclusions
From all this mass of facts and theories, can one extract a practical 
modus operandi? I like this series of simple questions which Moore and 
Jessiman suggest should be asked in assessing each particular case :
1. At what stage in the natural course of the disease is the patient 
when first seen?
2. W hat has surgery, radical or local, to offer?
3. Has irradiation therapy a place?
4. Is the tumour hormone-dependent?
5. If so, what is the probable source of the hormone?
6. Can its removal by hormonal therapy or endocrine operations help 
the case?
These may be simple questions to a s k ; they are still not so easy 
to answer. But a great deal can be learnt about the activity of any 
growth by a careful study of symptoms and signs including discoverable 
visceral and soft tissue metastases and the radiological findings, and by 
the application of the tests previously described.
One feels, however, that a complete reorientation of thought on the 
problem is urgently needed. The first essential in any case is the dis­
covery of the hormone dependence of the growth. We should aim to 
achieve this before and not after the appearance of metastases. If 
this were possible, then the unfortunately larger group of non-dependent 
growths would be treated by a judicious mixture of surgery and deep X-ray 
therapy. To consolidate my own ideas, I believe that in this group, radical 
mastectomy alone is the treatment of choice for genuine clinical Stage I 
growths in the outer quadrants; that Stage I growths in the inner 
quadrants call for radical mastectomy together with irradiation of the 
internal mammary and supra-clavicular fields of lymphatic spread and 
that, for all other cases, local and non-mutilating surgery, with carefully 
planned deep X-ray therapy, is indicated.
In the hormone-dependent class, there would seem every indication 
for proceeding with a similar basic plan, reinforced without delay by 
surgical castration and supportive cortisone therapy. In those cases which 
break down under such a regime, hypophysectomy should be seriously 
considered.
One realises that such a simplification and condensation of thought 
is full of fallacies, but it does embody two principles— that of turning a 
full battery of therapeutic guns, carefully arranged and accurately trained, 
on to the target of growth and, secondly, that of sparing the patient as 
much discomfort and disfigurement as possible in the process.
Thus, while sadly cure of the disease still eludes us, care of the patient 
can be exercised to the full.
